A recent study of Psilocybin—the main ingredient in magic mushrooms—has shown promise for those who do not respond to oral anti-depressants.
A new study maps the enzymes and genes of psilocybin, the primary hallucinogen in magic mushrooms, laying the groundwork for future mass-production.
[DIGEST: Scientific American, Lancet Psychiatry, Huffington Post] The first clinical trial to use psilocybin, the active compound in “magic mushrooms,” to treat major depression shows promise in a small but breakthrough study. Researchers from Imperial College London gave psilocybin to 12 people suffering from severe depression. One week after receiving an oral dose of the … Continued